Press Releases (2004)

$20 Rebate Now Available For Users Of Penlac® Nail Lacquer

On-line offer provides valuable discount for nail fungus patients

BERWYN, PA — August 13, 2004 — People who are sufferers of nail fungus, and who are prescribed Penlac® Nail Lacquer (ciclopirox) Topical Solution, 8% can now benefit from a new program introduced by Dermik Laboratories offering a rebate of up to $20 on their prescription of Penlac® 6.6ml. The Penlac® Rebate Program is a Web-based offer that enables Penlac® patients to save money by simply visiting www.penlac.com, printing and completing the electronic form, and mailing the completed certificate with their original pharmacy receipt to the address provided on the Web site.

According to Tom Sabia, Penlac® product manager at Dermik, "We recognize that combating nail fungus is a commitment that patients must make to manage the condition. Dermik is taking this step to demonstrate our commitment to the overall patient population. Penlac® is the only FDA-approved topical medication for the treatment of onychomycosis and provides a safe alternative for patients who are not candidates for oral medications."

Sabia added that the rebate offer expires January 31, 2005. Full terms and conditions are outlined on the online rebate certificate.

About Penlac®
Penlac® is a topical prescription for mild to moderate fungal nail infections. Regular visits to your health care professional for the removal of unattached, infected nails may be required. If you have diabetes, it is important to talk to your health care professional about nail care. The most common side effects are redness around nails, nail shape change, irritation, ingrown toenail and discoloration.

About Dermik Laboratories
Penlac® is marketed by Dermik Laboratories. Dermik Laboratories conducts the North American business of Aventis Dermatology, the global dermatology unit of Aventis Pharmaceuticals Inc. Dermik is dedicated to providing innovative dermatological products to satisfy the needs of health care providers and patients. Dermik has expanded its core business with a new aesthetic/cosmetic dermatology focus, and continues its strong commitment to treatments for traditional skin and nail conditions, including acne, nail fungus, pre-cancerous skin lesions, psoriasis and rosacea. Its corporate headquarters is located in Berwyn, PA. Please visit our website: www.dermik.com as well as www.penlac.com.

About Aventis
Aventis Pharmaceuticals conducts the U.S. prescription drug business of Aventis. With headquarters in Bridgewater, NJ, Aventis Pharmaceuticals focuses its activities on important therapeutic areas such as cardiology, oncology, anti-infectives, arthritis, allergy and respiratory, diabetes, and the central nervous system.

Statements in this news release containing projections or estimates of revenues, income, earnings per share, capital expenditures, capital structure, or other financial items; plans and objectives relating to future operations, products, or services; future economic performance; or assumptions underlying or relating to any such statements, are forward-looking statements subject to risks and uncertainties. Actual results could differ materially depending on factors such as the timing and effects of regulatory actions, the results of clinical trials, the company's relative success developing and gaining market acceptance for new products, the outcome of significant litigation, and the effectiveness of patent protection. Additional information regarding risks and uncertainties is set forth in the current Annual Report on Form 20-F of Aventis on file with the Securities and Exchange Commission and in the current Annual Report – "Document de Référence" – on file with the "Autorité des marchés financiers" in France.